7 | | The goal is to produce a draft document outlining topics such as |
8 | | - the kinds of experiments users can participate in |
9 | | - how to encourage user opt-in |
10 | | - what to do (and not) about IRBs |
11 | | - what developers of applications and infrastructure services should tell users (data gathering, reliability, duration, ...) |
12 | | - other topics raised at GEC3 and GEC4. |
| 7 | The objective is to add content to the DRAFT document: “GENI End-User Opt-In Overview” (working title). |
| 8 | |
| 9 | To date, five end-user opt-in use cases have been identified: |
| 10 | |
| 11 | • Use Case 1: User opt-in to GENI experiment for service |
| 12 | • Use Case 2: Wholesale opt-in to GENI of traffic |
| 13 | • Use Case 3: A disruptive GENI experiment |
| 14 | • Use Case 4: Opt-in of user resources to a GENI experiment |
| 15 | • Use Case 5: Gathering data involving opt-in users in a GENI experiment |
| 16 | |
| 17 | These use cases then drive requirements on capabilities that are being included into GENI, including: |
| 18 | |
| 19 | • Capability 1: Gateway from GENI to another network, e.g., the Internet |
| 20 | • Capability 2: Contribution (or association) of a user’s node to an experiment on GENI |
| 21 | • Capability 3: Gathering logs and experiment data on GENI (some possibly user-identifiable) and managing their distribution |
| 22 | |
| 23 | Finally, we expect various common policy themes to arise from an examination of the policies and best practices required for each use case, such as: |
| 24 | |
| 25 | • Privacy policies for end-users |
| 26 | • Disclosure policies |
| 27 | |
| 28 | |
| 29 | |
| 30 | For each use case, we want to better understand and write down: |
| 31 | the players, their motivation and relationships; |
| 32 | major issues (incentives, risks to consider, etc.) |
| 33 | and a first cut at policies and best practices when operating in a GENI environment. |
| 34 | |
| 35 | |
| 36 | We want to finish this meeting with a better understanding, and a few pages of text for each use case. Then, we hope to have a baseline view of GENI opt-in that can be expanded in the coming months. |
| 37 | |
| 38 | |
| 39 | |